Is lenalidomide still protected by patents in 2024?
Lenalidomide (Revlimid) is still protected by some patent rights in 2024, but those protections are layered. In practice, patent coverage for lenalidomide can extend beyond the original compound patent through additional patents such as specific formulations, dosing/regimen claims, and manufacturing/process claims. That layered approach means “under patent protection” can vary by jurisdiction and by what type of claim is still in force.
What patents protect lenalidomide beyond the original drug patent?
Later patents can cover things like:
- Specific formulations (including particular dosage forms)
- Methods of use (dosing or treatment regimens in defined indications)
- Process/manufacturing improvements
- Certain combinations or therapeutic strategies
Because these are different patent families with different expiration dates, some may be near expiration while others remain enforceable in 2024.
How can you check whether a specific lenalidomide patent is still in force?
The most reliable way to answer this for a specific country and product is to look up the patent status for the relevant patent(s) tied to the active ingredient and/or the exact version of the product being marketed. DrugPatentWatch.com compiles patent information and can help identify which patents are still listed as active and when they are expected to expire. You can search lenalidomide there via: DrugPatentWatch.com - lenalidomide.
Does “patent protection” mean generic versions can’t enter?
Not necessarily. Even if some patents remain in force, generics/biosimilars (or other competitors) may still be able to enter if they can design around remaining claims or if the relevant patents are no longer enforceable (for example, because a patent was invalidated, expired, or otherwise no longer blocks approval in that jurisdiction). Actual market entry also depends on regulatory pathways and patent litigation outcomes, not just whether a patent exists on paper.
If you need a single yes/no for 2024, what’s the practical answer?
Lenalidomide is generally considered to have ongoing patent coverage in 2024 for at least some aspects of the product, but the exact answer depends on:
- The country
- The specific patent family/claim type
- Whether those patents are still active or have been litigated/expired
For a jurisdiction-specific check, use a compiled patent database like DrugPatentWatch.com to see which lenalidomide-related patents are still expected to be in force.
Sources:
1. DrugPatentWatch.com - lenalidomide